NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES THE SHELF PROSPECTUS SUPPLEMENT, THE CORRESPONDING BASE SHELF PROSPECTUS AND ANY AMENDMENT TO THE DOCUMENTS ARE ACCESSIBLE THROUGH SEDAR+ OR WILL BE ACCESSIBLE THROUGH SEDAR+ WITHIN 2 BUSINESS DAYS, AS APPLICABLE TORONTO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Andean Precious Metals Corp. (“Andean” or the “Company”) (TSX: APM) (OTCQX: ANPMF) is pleased to announce that it has entered into an agreement with PMB Partners LP (t ...

Core Insights - DiamiR Biosciences Corp. and Aptorum Group Limited are set to present at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, showcasing innovative blood-based diagnostic tests for brain health and neurodegeneration [1][4] Presentation Details - The presentations will occur on December 3, 2025, at the Hilton San Diego Bayfront, focusing on microRNA classifiers and their role in classifying cognitive impairment stages [2] - Poster 225 will discuss developing microRNA classifiers enriched in brain and inflammation in plasma samples, in collaboration with New York University [2] - Poster 240 will characterize stages of neurodegeneration using circulating brain-enriched and inflammation-associated microRNAs, in collaboration with the University of Pennsylvania [3] Merger Information - Aptorum Group and DiamiR have entered into a definitive agreement for an all-stock merger, with DiamiR becoming a wholly-owned subsidiary of Aptorum upon completion, expected in Q1 2026 [5] - The merger is subject to stockholder approval and customary closing conditions [5] Company Profiles - Aptorum Group is a clinical stage biopharmaceutical company focused on developing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [6] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions, supported by over 50 issued patents [8]

Registration No. [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTORUM GROUP LIMITED (Exact Name of Registrant as Specified in its Charter) Cayman Islands 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 17 Hanover Square London W1S 1BN, United Kingdom Telephone: +44 20 80929299 (Address, ...

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Dreamland experiencing the largest drop of 80.98% [1] - Other notable declines include Tianruixiang at 46.5%, Zhiling Group at 29.96%, and Mercurity Fintech at 26.69% [1] - The trading volumes for these stocks varied, with Dreamland having a transaction amount of 37.5017 million and Mercurity Fintech at 8.0682 million [1] Group 2 - Dreamland's latest price is reported at 1.160, down by 4.940 [1] - Tianruixiang's latest price is 1.260, down by 1.095 [1] - Zhiling Group's latest price is 1.660, down by 0.710 [1]

Core Viewpoint - Aptorum Group Limited has announced a registered direct offering of 1,000,000 Class A ordinary shares at a price of $2.00 per share, with potential additional gross proceeds of up to $4 million from unregistered warrants [1][3]. Group 1: Offering Details - The offering is expected to generate gross proceeds of $2 million before deducting fees and expenses [3]. - The company will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per share, which will be exercisable upon issuance and expire in twenty-four months [1][3]. - The closing of the offering is anticipated to occur around October 14, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund expenses related to the merger agreement between Aptorum and DiamiR Biosciences Corp., as well as for general working capital for both companies pending the merger's closing [3]. Group 3: Regulatory Information - The ordinary shares are being offered under a "shelf" registration statement that was declared effective by the SEC on January 19, 2023 [4]. - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under applicable securities laws [5].

Core Viewpoint - Aptorum Group Limited announces the addition of Dr. Laura A. Philips to its board of directors following the merger with DiamiR Biosciences Corp, aiming to enhance its strategic initiatives in addressing aging-related diseases [1][3]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [8]. - DiamiR Biosciences is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions, utilizing a proprietary platform technology based on microRNA signatures [9]. Leadership Changes - Dr. Laura A. Philips, co-founder and CEO of Spheryx, Inc., joins Aptorum's board as an independent director, bringing extensive experience in life sciences and technology [2][3]. - Following the merger, Dr. Kira Sheinerman from DiamiR will join the combined board, and Dr. Alidad Mireskandari will assume the role of President and COO [4][5]. Strategic Goals - The merger is expected to strengthen market awareness and execution capabilities for both Aptorum and DiamiR, particularly in the development of tests for Alzheimer's and other brain diseases [3][4]. - The transaction is anticipated to close in the fourth quarter of 2025, subject to stockholder approval and customary closing conditions [3].

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Top Gainers - Nature's Sunshine Products (UPC) saw a remarkable increase of 82.98%, closing at a price of 9.460, with a trading volume of 235 million [1] - Melco Resorts & Entertainment (MSC) rose by 19.23%, reaching a price of 4.680, with a trading volume of 48,500 [1] - I-Mab (IMAB) increased by 16.02%, closing at 5.070, with a trading volume of 29.76 million [1] - Zai Lab (APM) experienced a gain of 15.31%, closing at 2.410, with a trading volume of 1.6078 million [1] - China Natural Resources (CHNR) rose by 14.84%, closing at 5.700, with a trading volume of 8.8604 million [1]

FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Exhibit 99.1 As filed with the United States Securities and Exchange Commission on October 6, 2025 Registration No. 333-290742 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ Aptorum Group Limited (Exact name of registrant as specified in its charter) _________________________________ Cayman Islands* 2834 Not Applicable (State or Other Jurisdiction of (Primary Standard Industrial (I.R.S ...

Core Viewpoint - Aptorum Group Limited and DiamiR Biosciences Corp. are collaborating on a merger, with DiamiR set to become a wholly-owned subsidiary of Aptorum, pending shareholder approval and customary closing conditions [3]. Company Overview Aptorum Group - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [4]. DiamiR Biosciences - DiamiR is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions and other diseases, utilizing a proprietary platform technology protected by over 50 patents worldwide [5]. Merger Details - The merger between Aptorum and DiamiR was announced on July 16, 2025, and is expected to close in the fourth quarter of 2025, subject to stockholder approval [3]. - DiamiR's CEO, Alidad Mireskandari, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [2].

Core Viewpoint - Chinese concept stocks experienced significant declines, with the top five losers showing steep drops in their stock prices, indicating potential market volatility and investor concerns [1] Group 1: Stock Performance - Dongfang Culture (OCG) saw a decline of 17.19%, closing at 2.890, with a trading volume of 585,300 [1] - Renkong Technology (RCON) dropped by 12.69%, ending at 2.270, with a trading volume of 1,132,700 [1] - Zhiling Group (APM) fell by 11.74%, closing at 2.330, with a trading volume of 6,809,100 [1] - Luda Technology (LUD) decreased by 10.66%, finishing at 5.280, with a trading volume of 75,800 [1] - Dingxin Holdings (DXST) experienced a drop of 10.31%, closing at 1.130, with a trading volume of 60,800 [1]